Redx Pharma PLC
LSE:REDX
Redx Pharma PLC
Income from Continuing Operations
Redx Pharma PLC
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
R
|
Redx Pharma PLC
LSE:REDX
|
Income from Continuing Operations
-£33.2m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
GlaxoSmithKline PLC
LSE:GSK
|
Income from Continuing Operations
£4.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Income from Continuing Operations
$6.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
Indivior PLC
LSE:INDV
|
Income from Continuing Operations
$5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Income from Continuing Operations
$192m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Income from Continuing Operations
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Redx Pharma PLC's Income from Continuing Operations?
Income from Continuing Operations
-33.2m
GBP
Based on the financial report for Sep 30, 2023, Redx Pharma PLC's Income from Continuing Operations amounts to -33.2m GBP.
What is Redx Pharma PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-30%
Over the last year, the Income from Continuing Operations growth was -84%. The average annual Income from Continuing Operations growth rates for Redx Pharma PLC have been -53% over the past three years , -30% over the past five years .